NOVO NORDISK A/S |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 919 DKK | -0.89% |
|
-0.12% | +31.21% |
| 01:53pm | Fire Breaks Out in Novo Nordisk Denmark Office Building | MT |
| 12:39pm | European shares to hit pause before rising again in 2025 | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
927.2
DKK
Average target price
909.2
DKK
Spread / Average Target
-1.94%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +31.21% | 598B | |
| +37.78% | 723B | |
| -3.51% | 364B | |
| +19.94% | 331B | |
| +5.14% | 288B | |
| +15.94% | 244B | |
| +9.65% | 210B | |
| -5.03% | 208B | |
| +9.32% | 169B | |
| -0.80% | 162B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Danish Medicines Agency Says Type 2 Diabetes Patients Should Start Treatment With 'Cheaper' Drugs
